Immune Response Testing Market Report 2026

The immune response testing market size has grown rapidly in recent years. It will grow from $16.36 billion in 2025 to $18.09 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increasing prevalence of immune-related disorders, wider use of antibody-based diagnostics, expansion of clinical immunology laboratories, growing adoption of ELISA testing methods, increased vaccine response monitoring.

The immune response testing market size is expected to see rapid growth in the next few years. It will grow to $26.76 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing demand for personalized immune profiling, rising use of immune monitoring in oncology and vaccines, expansion of point-of-care immune testing, growing integration of AI in diagnostic interpretation, increasing focus on early immune dysfunction detection. Major trends in the forecast period include increasing adoption of multiplex immune assays, rising use of cellular immune response analysis, growing integration of automated testing platforms, expansion of high-sensitivity diagnostic panels, enhanced focus on immune monitoring.

The rising prevalence of autoimmune diseases is expected to drive the growth of the immune response testing market in the coming years. Autoimmune diseases occur when the body’s immune system mistakenly attacks its own healthy cells and tissues. This growing prevalence is largely attributed to increased exposure to environmental pollutants, which can disrupt immune function and trigger such autoimmune reactions. Immune response testing supports the management of autoimmune diseases by providing precise insights into immune activity, enabling early diagnosis and personalized treatment plans. It facilitates improved disease monitoring and enhances patient outcomes through targeted therapy adjustments. For example, in February 2024, Arthritis Australia, a non-profit organization, estimated that 562,378 Australians would be living with rheumatoid arthritis (RA) in 2025, representing 14% of all arthritis cases that year. By 2040, this number is projected to rise by 33% to 748,721, an increase of 186,343 people compared with 2025. This trend indicates that the rising prevalence of autoimmune diseases is fueling the growth of the immune response testing market.

Leading companies in the immune response testing market are focusing on innovative solutions, such as immune profiling technologies, to meet the growing demand for advanced diagnostics in post-viral syndromes and adaptive immunity assessment. Immune profiling technologies provide a comprehensive analysis of the immune system, evaluating both cellular and humoral responses, and offer more detailed insights than traditional serological tests, which mainly detect antibody levels. For instance, in April 2024, Virax Biolabs Group Limited, a UK-based biotechnology firm, launched a portfolio of immune profiling solutions at ESCMID Global 2024, targeting the evaluation of adaptive immunity in post-viral conditions. These solutions incorporate advanced assays, including multi-parametric flow cytometry and targeted biomarker panels, enabling precise characterization of immune cell subsets and functional responses. They feature high sensitivity, customizable panels for different post-viral syndromes, and integration with digital reporting platforms for streamlined data interpretation. Applications range from clinical research to personalized patient monitoring, providing early detection of immune dysfunction and supporting therapeutic decision-making.

In July 2024, Thermo Fisher Scientific Inc., a US-based biotechnology company, acquired Olink Holding AB for $3.1 billion. This acquisition strengthens Thermo Fisher’s position in life sciences by integrating Olink’s advanced proteomics capabilities, accelerating research, and advancing precision medicine to improve patient outcomes. Olink Holding AB, based in Sweden, specializes in immune response testing through protein biomarker detection, adding significant value to Thermo Fisher’s portfolio.

Major companies operating in the immune response testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare GmbH, Becton Dickinson and Company, Quest Diagnostics Incorporated, Eurofins Scientific SE, PerkinElmer Inc., bioMérieux SA, Bruker Corporation, Beckman Coulter Inc., Bio-Rad Laboratories Inc., Qiagen N.V., DiaSorin S.p.A., EUROIMMUN Medizinische Labor diagnostika AG, NanoString Technologies Inc., GenScript Biotech Corporation, Cell Signaling Technology Inc., Sysmex Corporation, Ortho Clinical Diagnostics, Randox Laboratories Ltd., Merck KGaA.

North America was the largest region in the immune response testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immune response testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immune response testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the immune response testing market by increasing costs of imported reagents, assay kits, laboratory instruments, sensors, and diagnostic consumables. Diagnostic laboratories and research institutes in North America and Europe are most affected due to dependence on imported testing materials, while Asia-Pacific faces cost pressure on advanced assay production. These tariffs are raising testing costs and affecting procurement cycles. However, they are also encouraging domestic reagent manufacturing, regional diagnostic kit development, and local production of immune testing platforms.

The immune response testing market research report is one of a series of new reports that provides immune response testing market statistics, including immune response testing industry global market size, regional shares, competitors with a immune response testing market share, detailed immune response testing market segments, market trends and opportunities, and any further data you may need to thrive in the immune response testing industry. This immune response testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Immune response testing is a diagnostic procedure that assesses how the immune system responds to a specific antigen, pathogen, or vaccine. It measures the presence, type, and intensity of immune activity by detecting antibodies, immune cells, or cytokine levels in the body. This testing helps determine immunity status, diagnose immune-related conditions, and guide treatment or vaccination decisions.

The main categories of immune response testing include antibody testing, cytokine testing, cellular testing, and complement system testing. Antibody testing detects the presence of specific antibodies in the blood, indicating a past infection or an immune response to a particular pathogen. These tests are used in applications such as allergy testing, HIV diagnosis, cancer monitoring, rheumatoid arthritis, systemic lupus erythematosus, and others. They serve a broad range of end users, including hospitals, clinics, diagnostic laboratories, research institutes, and home care settings.

The immune response testing market includes revenues earned by entities through measuring immune cell activity, antibody detection and quantification, cytokine profiling, T-cell and B-cell functional assays, allergy testing, vaccine efficacy assessment, autoimmune disease testing, infectious disease immune response analysis, and monitoring immune-related therapy effectiveness. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.